GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Teleflex Inc (NYSE:TFX) » Definitions » Altman Z2-Score

Teleflex (Teleflex) Altman Z2-Score : 4.45 (As of Apr. 27, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Teleflex Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Teleflex has a Altman Z2-Score of 4.45, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Teleflex's Altman Z2-Score or its related term are showing as below:

TFX' s Altman Z2-Score Range Over the Past 10 Years
Min: 2.97   Med: 3.78   Max: 4.91
Current: 4.45

During the past 13 years, Teleflex's highest Altman Z2-Score was 4.91. The lowest was 2.97. And the median was 3.78.


Teleflex Altman Z2-Score Historical Data

The historical data trend for Teleflex's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teleflex Altman Z2-Score Chart

Teleflex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.62 3.54 4.25 4.52 4.45

Teleflex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.52 4.67 4.88 5.03 4.45

Competitive Comparison of Teleflex's Altman Z2-Score

For the Medical Instruments & Supplies subindustry, Teleflex's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teleflex's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Teleflex's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Teleflex's Altman Z2-Score falls into.



Teleflex Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Teleflex's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.1063+3.26*0.5456+6.72*0.0689+1.05*1.4365
=4.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $7,533 Mil.
Total Current Assets was $1,407 Mil.
Total Current Liabilities was $607 Mil.
Retained Earnings was $4,110 Mil.
Pre-Tax Income was 59.972 + 149.605 + 126.955 + 97.48 = $434 Mil.
Interest Expense was -25.791 + -23.192 + -17.762 + -18.337 = $-85 Mil.
Total Liabilities was $3,092 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1407.406 - 606.745)/7532.546
=0.1063

X2=Retained Earnings/Total Assets
=4109.736/7532.546
=0.5456

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(434.012 - -85.082)/7532.546
=0.0689

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(4440.988 - 0)/3091.558
=1.4365

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Teleflex has a Altman Z2-Score of 4.45 indicating it is in Safe Zones.


Teleflex  (NYSE:TFX) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Teleflex Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Teleflex's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Teleflex (Teleflex) Business Description

Traded in Other Exchanges
Address
550 East Swedesford Road, Suite 400, Wayne, PA, USA, 19087
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2022 sales), interventional (16%), anesthesia (14%), surgical (14%), interventional urology (12%), original-equipment manufacturing (10%), and all other (10%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.
Executives
Liam Kelly officer: EVP & President, International IDA BUSINESS AND TECHNOLOGY PARK, DUBLIN ROAD, ATHLONE L2 00000
Thomas E Powell officer: Senior Vice President & CFO C/O TOMOTHERAPY INCORPORATED, 1240 DEMING WAY, MADISON WI 53717
Stuart A Randle director 585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Jaewon Ryu director 950 N. GLEBE ROAD, SUITE 700, ARLINGTON VA 22203
Neena M Patil director JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Andrew A Krakauer director CANTEL MEDICAL CORP., 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Cameron P Hicks officer: Vice President, Global HR 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Klasko Stephen K. M.d. director 155 SOUTH LIMERICK ROAD, LIMERICK PA 19468
Jay White officer: VP & Pres, Global Commercial 3015 CARRINGTON MILL BLVD., MORRISVILLE NC 27560
Daniel V. Logue officer: VP, Gen Counsel & Secretary 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
John Deren officer: VP & Chief Accounting Officer 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
James J Leyden officer: VP, General Counsel, Secretary C/O INFRASOURCE SERVICES, INC, 500 WEST DUTTON MILL ROAD, ASTON PA 19014
James Winters officer: Vice President, Mfg and Supply 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Mario Wijker officer: Vice President, QARA 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Benson Smith director C/O ROCHESTER MEDICAL INC, ONE ROCHESTER MEDICAL DDRIVE, STEWARTVILLE MN 55976

Teleflex (Teleflex) Headlines

From GuruFocus

Q2 2023 Teleflex Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Teleflex Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2021 Teleflex Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2022 Teleflex Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Teleflex Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Teleflex Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Teleflex Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2021 Teleflex Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024